Crucell 2008
Combating Infectious Diseases
Annual Report and Form 20–F

• What Corporate Social Responsibility means to us
• What we do
• A CSR dilemma
• Crucell on its mission to combat infectious diseases
• Who we work with
• An example: Warm response to cold chain training
• How we do business
• A partnership with customers illustrated
• Crucell's PER.C6^® technology
• How we see our responsibility
• Crucell works in an environment that requires highly skilled employees
• Innovative safety approach
• Beyond legislation for safety
• Environmental impact
• An example: Combining vaccines for a diversity of benefits
• Energy & water consumption
• Economic aspects of our business

Crucell on its mission to combat infectious diseases

Crucell took part in two mass vaccination campaigns against cholera in 2008, with its oral vaccine Dukoral^®. The campaigns were organized in Myanmar and Zanzibar, two parts of the world where cholera epidemics are all too common.

Together with the International Vaccine Institute, Crucell distributed 137,000 doses of Dukoral^® in Myanmar to help prevent an outbreak of cholera following the cyclone that devastated the country. Another 100,000 doses of Dukoral^® were distributed in cooperation with the WHO in Zanzibar, Tanzania, as part of a clinical research program investigating the value of routine vaccination for establishing widespread protection of a population (herd immunity).

Cholera remains a significant threat to human health, particularly in developing countries where access to safe drinking water and adequate sanitation cannot be guaranteed. By making an essential tool available to international public health organizations, Crucell is delivering on its mission to combat infectious diseases.

An example: One world, one vaccine

To avert the threat of such a cholera outbreak in Myanmar, Crucell teamed up with the International Vaccine Institute (IVI), an international organization based in Korea, to send 137,000 doses of Dukoral^® to the cyclone survivors. This is enough to vaccinate at least 65,000 people. Crucell donated 50% of the doses and sold the other 50% to IVI at a price below production cost. The South Korean government supplied IVI with the necessary funds. Crucell shipped the vaccines in special ‘emergency’ packs, each containing 170 vials, rather than the usual two-dose package. This made transport and administration more efficient and helped to speed up the vaccination process.

Back to top ↑